• 1
    Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996; 87: 30693081.
  • 2
    Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999; 131: 207219.
  • 3
    Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164172.
  • 4
    Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993; 82: 22352238.
  • 5
    Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993; 12: 509516.
  • 6
    Socié G, Salooja N, Cohen A, et al., for the Late Effect Working Party of the European Group for Blood and Marrow Transplantation. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101: 33733385.
  • 7
    Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995; 122: 254261.
  • 8
    Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997; 89: 16161620.
  • 9
    Allan NC, Richards SM, Shepherd PCA, et al. UK Medical Research Council randomized, multi-centre trial of interferon-α for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995; 345: 13921397.
  • 10
    Kantarjian H, O'Brien S, Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999; 17: 284292.
  • 11
    Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997; 337: 223229.
  • 12
    Baccarani M, Rosti G, de Vivo A,et al. A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. For the Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 2002; 99: 15271535.
  • 13
    Kantarjian HM, O'Brien S, Cortes J, et al. Complete cytogenetic and molecular responses to interferon-alfa-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003; 97: 10331041.
  • 14
    Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002; 20: 214220.
  • 15
    Bonifazi F, de Vivo A, Rosti G, Guilhot F, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98: 30743081.
  • 16
    Giles FJ, Kantarjian H, O'Brien S, et al. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma. 2001; 41: 309319.
  • 17
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561566.
  • 18
    Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998; 4: 16611672.
  • 19
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 10311037.
  • 20
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042.
  • 21
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 BCR-ABL gene of the Philadelphia chromosome. Science. 1990; 247: 824830.
  • 22
    Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 1990; 87: 66496653.
  • 23
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645652.
  • 24
    Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res. 2002; 8: 21772187.
  • 25
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 19281937.
  • 26
    Kantarjian H, O'Brien S, Cortes J, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8: 21672176.
  • 27
    Sawyers C, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99: 35303539.
  • 28
    Kantarjian H, Cortes J, O'Brien S, et al. Imatinib meylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002; 99: 35473553.
  • 29
    Kantarjian H, O'Brien S, Cortes J, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002; 100: 15901595.
  • 30
    Kantarjian H, Cortes J, O'Brien, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003; 101: 97100.
  • 31
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly-diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 9941004.
  • 32
    Benson BA, Hartz A. A comparison of observation studies and randomized, controlled trials. N Engl J Med. 2000; 342: 18781886.
  • 33
    Concato J, Shah N, Horwitz RI. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342: 18781892.
  • 34
    Cortes J, Talpaz M, O'Brien S, et al. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily [abstract]. Blood. 2002; 100: 95a.
  • 35
    O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999; 93: 41494153.
  • 36
    O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002; 94: 20242032.
  • 37
    Sokal J, Cox EB, Baccarani M, Tura S, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984; 63: 789799.
  • 38
    Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850858.
  • 39
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc. 1972; 34: 187220.